5 completed, 2 terminated, 2 unknown, 1 active not recruiting. 10 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Completed 5, Terminated 2, Unknown 2, Active not recruiting 1 |
Follow Pompe Disease: new trials by email Literature Review of Pompe Disease trials Research Report on Pompe Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 Years Avalglucosidase Alfa - Glycogen Storage Disease Type II Late Onset, Pompe Disease (Late-onset) | Phase 4 | Active not recruiting | Iris Plug | 6 | 2022-10-13 | 2026-06-17 |
| Immune Modulation Therapy for Pompe Disease Rituximab, intravenous immune globulin, Bortezomib - Pompe Disease | Phase 4 | Unknown | National Taiwan University Hospital | 8 | 2015-08-01 | 2016-04-15 |
| Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease alglucosidase alfa - Pompe Disease, Glycogen Storage Disease Type II (GSD II) | Phase 4 | Completed | Genzyme, a Sanofi Company | 21 | 2014-11-03 | 2022-03-28 |
| CPAP for Infantile Pompe Disease continuous positive airway pressure - Pompe Disease | Phase 4 | Unknown | National Taiwan University Hospital | 3 | 2014-06-01 | 2015-04-01 |
| Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease Salbutamol - Pompe Disease | Phase 4 | Completed | National Taiwan University Hospital | 14 | 2013-10-01 | 2016-09-20 |
| A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease Alglucosidase alfa - Pompe Disease | Phase 4 | Terminated | Genzyme, a Sanofi Company | 113 | 2012-03-01 | 2015-12-08 |
| An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease Alglucosidase Alfa, Methotrexate, Rituximab - Pompe Disease, Glycogen Storage Disease Type II | Phase 4 | Completed | Genzyme, a Sanofi Company | 4 | 2009-10-01 | 2014-05-13 |
| Immune Tolerance Induction Study Myozyme® (alglucosidase alfa) - Pompe Disease, Glycogen Storage Disease Type II (GSD-II) | Phase 4 | Terminated | Genzyme, a Sanofi Company | 4 | 2008-12-14 | 2022-04-07 |
| Growth and Development Study of Alglucosidase Alfa alglucosidase alfa - Pompe Disease, Glycogen Storage Disease Type II (GSD-II) | Phase 4 | Completed | Genzyme, a Sanofi Company | 12 | 2008-08-26 | 2022-08-26 |
| High Dose or High Dose Frequency Study of Alglucosidase Alfa alglucosidase alfa - Pompe Disease, Glycogen Storage Disease Type II (GSD-II) | Phase 4 | Completed | Genzyme, a Sanofi Company | 13 | 2007-05-01 | 2014-03-07 |
Glycogen Storage Disease Type II (10) · Heartburn (1)
Brain Diseases (10) · Brain Diseases, Metabolic (10) · Brain Diseases, Metabolic, Inborn (10) · Carbohydrate Metabolism, Inborn Errors (10) · Central Nervous System Diseases (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Glycogen Storage Disease (10) · Lysosomal Storage Diseases (10) · Lysosomal Storage Diseases, Nervous System (10) · Metabolic Diseases (10) · Metabolism, Inborn Errors (10) · Nervous System Diseases (10) · Nutritional and Metabolic Diseases (10) · Pathological Conditions, Signs and Symptoms (1)
GAA protein, human (6) · Methotrexate (2) · Rituximab (2) · Albuterol (1) · Bortezomib (1) · Continuous Positive Airway Pressure (1) · Immunoglobulins, Intravenous (1)
Genzyme, a Sanofi Company (6) · National Taiwan University Hospital (3) · Iris Plug (1)
United States (6) · Taiwan (3) · Australia (1) · Bulgaria (1) · Canada (1) · India (1) · Israel (1) · Netherlands (1) · Russia (1) · Ukraine (1) · United Kingdom (1)
Yin-Hsiu Chien, MD, PhD (2) · Nadine van der Beek, MD PHD (1) · Yin-Hsiu Chien (1)
PMID 29565424, PMID 31086307, PMID 34420548, PMID 36214004, PMID 37705424, PMID 38715621
2015 (1), 2019 (1)